Biomarkers /
BCR-ABL1 Fusion
Back to Biomarkers List
Overview
Biomarker-Directed Therapies
BCR-ABL1 Fusion is a predictive biomarker for use of dasatinib, bosutinib, nilotinib, imatinib, and ponatinib in patients.
Of the therapies with BCR-ABL1 Fusion as a predictive biomarker, 4 are FDA-approved and 5 have NCCN guidelines in at least one clinical setting.
Chronic myeloid leukemia and acute lymphoblastic leukemia have the most therapies targeted against BCR-ABL1 Fusion or its related pathways [5].
Bosutinib +
Acute Lymphoblastic Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
Chronic Myeloid Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
Dasatinib +
Acute Lymphoblastic Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (FDA, NCCN), Relapse (NCCN), Treatment Induction (NCCN) | |
| Note: Not recommended as a single agent for patients 40 years and older with Ph-positive ALL. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (NCCN), Refractory (NCCN), Relapse (NCCN) | |
| Note: Resistance to prior TKI-containing therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Refractory (NCCN) |
Chronic Myeloid Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (MCG), Relapse (FDA), Treatment Induction (FDA, NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) |
Imatinib +
Acute Lymphoblastic Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (FDA), Relapse (FDA) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Refractory (NCCN) |
Chronic Myeloid Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Treatment Induction (FDA, NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Refractory (NCCN) |
Nilotinib +
Acute Lymphoblastic Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) | |
| Note: Resistance to prior TKI-containing therapy. |
Chronic Myeloid Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (FDA), Treatment Induction (FDA, NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (FDA, NCCN), Relapse (NCCN) | |
| Note: Resistance or intolerant to prior therapy that included imatinib. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Refractory (NCCN), Relapse (NCCN) | |
| Note: Applies if the cancer is resistant or intolerant to prior therapy that included imatinib. |
Ponatinib +
Acute Lymphoblastic Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA, NCCN), Refractory (FDA, NCCN), Relapse (FDA, NCCN), Treatment Induction (FDA, NCCN) | |
| Note: Indicated for T315I-positive Ph+ ALL. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA, NCCN), Refractory (FDA, NCCN), Relapse (FDA, NCCN), Treatment Induction (FDA, NCCN) | |
| Note: Indicated for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated. |
Chronic Myeloid Leukemia -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Refractory (FDA, NCCN), Relapse (FDA, NCCN) | |
| Note: Indicated for T315I-positive CML (chronic phase, accelerated phase, or blast phase). |
Clinical Trials
BCR-ABL1 Fusion serves as an inclusion eligibility criterion in 241 clinical trials, of which 155 are open and 86 are closed. Of the trials that contain BCR-ABL1 Fusion as an inclusion criterion, 2 are early phase 1 (1 open), 54 are phase 1 (25 open), 35 are phase 1/phase 2 (22 open), 108 are phase 2 (79 open), 4 are phase 2/phase 3 (3 open), 26 are phase 3 (18 open), 7 are phase 4 (5 open), and 5 are no phase specified (2 open).
Trials with BCR-ABL1 Fusion in the inclusion eligibility criteria most commonly target acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, B-cell acute lymphoblastic leukemia, and acute biphenotypic leukemia [5].
Fludarabine, cyclophosphamide, cytarabine, allogeneic hematopoietic stem cell transplantation, and methotrexate are the most frequent therapies in trials with BCR-ABL1 Fusion as an inclusion criteria [5].
Significance of BCR-ABL1 Fusion in Diseases
Chronic Myeloid Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 115 clinical trials for chronic myeloid leukemia, of which 74 are open and 41 are closed. Of the trials that contain BCR-ABL1 Fusion and chronic myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 24 are phase 1 (11 open), 19 are phase 1/phase 2 (12 open), 52 are phase 2 (40 open), 11 are phase 3 (7 open), 5 are phase 4 (3 open), and 3 are no phase specified (1 open) [5].
Dasatinib, nilotinib, bosutinib, imatinib, and ponatinib have evidence of efficacy in patients with BCR-ABL1 Fusion in chronic myeloid leukemia [5].
Acute Lymphoblastic Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 92 clinical trials for acute lymphoblastic leukemia, of which 59 are open and 33 are closed. Of the trials that contain BCR-ABL1 Fusion and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 23 are phase 1 (11 open), 10 are phase 1/phase 2 (8 open), 43 are phase 2 (28 open), 2 are phase 2/phase 3 (2 open), 7 are phase 3 (6 open), 2 are phase 4 (2 open), and 3 are no phase specified (1 open) [5].
Ponatinib, bosutinib, dasatinib, imatinib, and nilotinib have evidence of efficacy in patients with BCR-ABL1 Fusion in acute lymphoblastic leukemia [5].
Acute Myeloid Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 117 clinical trials for acute myeloid leukemia, of which 67 are open and 50 are closed. Of the trials that contain BCR-ABL1 Fusion and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 32 are phase 1 (15 open), 21 are phase 1/phase 2 (15 open), 48 are phase 2 (29 open), 3 are phase 2/phase 3 (2 open), 9 are phase 3 (5 open), and 2 are no phase specified (0 open) [5].
Myelodysplastic Syndromes +
BCR-ABL1 Fusion is an inclusion criterion in 75 clinical trials for myelodysplastic syndromes, of which 44 are open and 31 are closed. Of the trials that contain BCR-ABL1 Fusion and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 24 are phase 1 (11 open), 12 are phase 1/phase 2 (10 open), 31 are phase 2 (19 open), 2 are phase 2/phase 3 (1 open), 2 are phase 3 (2 open), and 2 are no phase specified (0 open) [5].
Hodgkin Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 23 clinical trials for hodgkin lymphoma, of which 12 are open and 11 are closed. Of the trials that contain BCR-ABL1 Fusion and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 10 are phase 2 (6 open), and 1 is no phase specified (0 open) [5].
Multiple Myeloma +
BCR-ABL1 Fusion is an inclusion criterion in 20 clinical trials for multiple myeloma, of which 13 are open and 7 are closed. Of the trials that contain BCR-ABL1 Fusion and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), 8 are phase 2 (5 open), and 1 is no phase specified (0 open) [5].
Non-Hodgkin Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 19 clinical trials for non-hodgkin lymphoma, of which 11 are open and 8 are closed. Of the trials that contain BCR-ABL1 Fusion and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 9 are phase 2 (6 open) [5].
B-Cell Acute Lymphoblastic Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 18 clinical trials for B-cell acute lymphoblastic leukemia, of which 15 are open and 3 are closed. Of the trials that contain BCR-ABL1 Fusion and B-cell acute lymphoblastic leukemia as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 7 are phase 2 (5 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [5].
Acute Biphenotypic Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 17 clinical trials for acute biphenotypic leukemia, of which 8 are open and 9 are closed. Of the trials that contain BCR-ABL1 Fusion and acute biphenotypic leukemia as inclusion criteria, 7 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), 7 are phase 2 (3 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [5].
Chronic Myelomonocytic Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 16 clinical trials for chronic myelomonocytic leukemia, of which 11 are open and 5 are closed. Of the trials that contain BCR-ABL1 Fusion and chronic myelomonocytic leukemia as inclusion criteria, 6 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), 6 are phase 2 (5 open), and 1 is no phase specified (0 open) [5].
Chronic Lymphocytic Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 15 clinical trials for chronic lymphocytic leukemia, of which 9 are open and 6 are closed. Of the trials that contain BCR-ABL1 Fusion and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 5 are phase 1/phase 2 (3 open), and 4 are phase 2 (4 open) [5].
Acute Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 11 clinical trials for acute leukemia, of which 4 are open and 7 are closed. Of the trials that contain BCR-ABL1 Fusion and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [5].
Mantle Cell Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 11 clinical trials for mantle cell lymphoma, of which 5 are open and 6 are closed. Of the trials that contain BCR-ABL1 Fusion and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [5].
Burkitt Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 10 clinical trials for Burkitt lymphoma, of which 4 are open and 6 are closed. Of the trials that contain BCR-ABL1 Fusion and Burkitt lymphoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [5].
Anaplastic Large Cell Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 9 clinical trials for anaplastic large cell lymphoma, of which 4 are open and 5 are closed. Of the trials that contain BCR-ABL1 Fusion and anaplastic large cell lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [5].
Myeloproliferative Neoplasm +
BCR-ABL1 Fusion is an inclusion criterion in 9 clinical trials for myeloproliferative neoplasm, of which 5 are open and 4 are closed. Of the trials that contain BCR-ABL1 Fusion and myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [5].
Follicular Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 8 clinical trials for follicular lymphoma, of which 3 are open and 5 are closed. Of the trials that contain BCR-ABL1 Fusion and follicular lymphoma as inclusion criteria, 3 are phase 1 (2 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [5].
Juvenile Myelomonocytic Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 8 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 5 are closed. Of the trials that contain BCR-ABL1 Fusion and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [5].
Marginal Zone Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 8 clinical trials for marginal zone lymphoma, of which 3 are open and 5 are closed. Of the trials that contain BCR-ABL1 Fusion and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [5].
Lymphoblastic Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 7 clinical trials for lymphoblastic lymphoma, of which 5 are open and 2 are closed. Of the trials that contain BCR-ABL1 Fusion and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [5].
Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 7 clinical trials for lymphoma, of which 3 are open and 4 are closed. Of the trials that contain BCR-ABL1 Fusion and lymphoma as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (0 open), 2 are phase 2 (2 open), and 2 are phase 3 (1 open) [5].
Myelofibrosis +
BCR-ABL1 Fusion is an inclusion criterion in 7 clinical trials for myelofibrosis, of which 3 are open and 4 are closed. Of the trials that contain BCR-ABL1 Fusion and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (1 open), and 3 are phase 2 (2 open) [5].
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 6 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 4 are closed. Of the trials that contain BCR-ABL1 Fusion and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [5].
Diffuse Large B-Cell Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 6 clinical trials for diffuse large B-cell lymphoma, of which 4 are open and 2 are closed. Of the trials that contain BCR-ABL1 Fusion and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), and 1 is phase 1/phase 2 (1 open) [5].
Mixed Phenotype Acute Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 6 clinical trials for mixed phenotype acute leukemia, of which 5 are open and 1 is closed. Of the trials that contain BCR-ABL1 Fusion and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [5].
Prolymphocytic Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 6 clinical trials for prolymphocytic leukemia, of which 3 are open and 3 are closed. Of the trials that contain BCR-ABL1 Fusion and prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [5].
Refractory Anemia With Excess Blasts +
BCR-ABL1 Fusion is an inclusion criterion in 6 clinical trials for refractory anemia with excess blasts, of which 2 are open and 4 are closed. Of the trials that contain BCR-ABL1 Fusion and refractory anemia with excess blasts as inclusion criteria, 2 are phase 1 (0 open), 3 are phase 2 (2 open), and 1 is no phase specified (0 open) [5].
Secondary Acute Myeloid Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 6 clinical trials for secondary acute myeloid leukemia, of which 6 are open and 0 are closed. Of the trials that contain BCR-ABL1 Fusion and secondary acute myeloid leukemia as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].
T-Cell Acute Lymphoblastic Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 6 clinical trials for T-cell acute lymphoblastic leukemia, of which 5 are open and 1 is closed. Of the trials that contain BCR-ABL1 Fusion and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [5].
Lymphoplasmacytic Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 5 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 4 are closed. Of the trials that contain BCR-ABL1 Fusion and lymphoplasmacytic lymphoma as inclusion criteria, 4 are phase 2 (1 open) and 1 is no phase specified (0 open) [5].
Myelodysplastic/Myeloproliferative Neoplasm +
BCR-ABL1 Fusion is an inclusion criterion in 5 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 4 are open and 1 is closed. Of the trials that contain BCR-ABL1 Fusion and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [5].
Small Lymphocytic Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 5 clinical trials for small lymphocytic lymphoma, of which 2 are open and 3 are closed. Of the trials that contain BCR-ABL1 Fusion and small lymphocytic lymphoma as inclusion criteria, 4 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome +
BCR-ABL1 Fusion is an inclusion criterion in 4 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain BCR-ABL1 Fusion and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [5].
Acute Undifferentiated Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 4 clinical trials for acute undifferentiated leukemia, of which 3 are open and 1 is closed. Of the trials that contain BCR-ABL1 Fusion and acute undifferentiated leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [5].
B-Cell Non-Hodgkin Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain BCR-ABL1 Fusion and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].
Double-Hit Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain BCR-ABL1 Fusion and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [5].
Refractory Anemia +
BCR-ABL1 Fusion is an inclusion criterion in 4 clinical trials for refractory anemia, of which 1 is open and 3 are closed. Of the trials that contain BCR-ABL1 Fusion and refractory anemia as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [5].
Therapy-Related Myelodysplastic Syndrome +
BCR-ABL1 Fusion is an inclusion criterion in 4 clinical trials for therapy-related myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain BCR-ABL1 Fusion and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].
Malignant Solid Tumor +
BCR-ABL1 Fusion is an inclusion criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain BCR-ABL1 Fusion and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].
Myelodysplastic Syndrome With Excess Blasts-2 +
BCR-ABL1 Fusion is an inclusion criterion in 3 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 2 are closed. Of the trials that contain BCR-ABL1 Fusion and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 3 are phase 2 (1 open) [5].
Plasma Cell Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 3 clinical trials for plasma cell leukemia, of which 1 is open and 2 are closed. Of the trials that contain BCR-ABL1 Fusion and plasma cell leukemia as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [5].
T-Cell Lymphoblastic Leukemia/Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain BCR-ABL1 Fusion and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [5].
Therapy-Related Acute Myeloid Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 3 clinical trials for therapy-related acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain BCR-ABL1 Fusion and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].
Acute Erythroid Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 2 clinical trials for acute erythroid leukemia, of which 2 are open and 0 are closed. Of the trials that contain BCR-ABL1 Fusion and acute erythroid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].
Acute Megakaryoblastic Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 2 clinical trials for acute megakaryoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain BCR-ABL1 Fusion and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].
Acute Promyelocytic Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 2 clinical trials for acute promyelocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain BCR-ABL1 Fusion and acute promyelocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is no phase specified (0 open) [5].
Adult T-Cell Leukemia/Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 2 clinical trials for adult T-cell leukemia/lymphoma, of which 0 are open and 2 are closed. Of the trials that contain BCR-ABL1 Fusion and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is phase 3 (0 open) and 1 is no phase specified (0 open) [5].
B-Cell Prolymphocytic Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 2 clinical trials for B-cell prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain BCR-ABL1 Fusion and B-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [5].
Burkitt Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain BCR-ABL1 Fusion and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [5].
Mature T-Cell And NK-Cell Lymphoma/Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain BCR-ABL1 Fusion and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [5].
Mature T-Cell And NK-Cell Neoplasm +
BCR-ABL1 Fusion is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain BCR-ABL1 Fusion and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [5].
Natural Killer Cell Lymphoblastic Leukemia/Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 2 clinical trials for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 1 is closed. Of the trials that contain BCR-ABL1 Fusion and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 2 are phase 2 (1 open) [5].
Peripheral T-Cell Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain BCR-ABL1 Fusion and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [5].
T-Cell Non-Hodgkin Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 2 clinical trials for T-cell non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain BCR-ABL1 Fusion and T-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (1 open) [5].
T-Cell Prolymphocytic Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 2 clinical trials for T-cell prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain BCR-ABL1 Fusion and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].
Acute Bilineal Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for acute bilineal leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and acute bilineal leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].
Acute Leukemia Of Ambiguous Lineage +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains BCR-ABL1 Fusion and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [5].
Acute Myeloid Leukemia With Myelodysplasia-Related Changes +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains BCR-ABL1 Fusion and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [5].
Adult Acute Lymphoblastic Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for adult acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and adult acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].
Aplastic Anemia +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [5].
B-Cell Lymphoblastic Leukemia/Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for B-cell lymphoblastic leukemia/lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and B-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].
B-Cell Lymphoblastic Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].
Desmoplastic Small Round Cell Tumor +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains BCR-ABL1 Fusion and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [5].
Ewing Sarcoma +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains BCR-ABL1 Fusion and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Histiocytic And Dendritic Cell Neoplasm +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Indolent Non-Hodgkin Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].
Mature B-Cell Lymphoma/Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains BCR-ABL1 Fusion and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [5].
Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BCR-ABL1 Fusion and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Mediastinal Large B-Cell Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BCR-ABL1 Fusion and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Melanoma +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains BCR-ABL1 Fusion and melanoma as inclusion criteria, 1 is no phase specified (0 open) [5].
Mixed Phenotype Acute Leukemia, B/Myeloid, NOS +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, B/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and mixed phenotype acute leukemia, B/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].
Mixed Phenotype Acute Leukemia, T/Myeloid, NOS +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].
Myelodysplastic Syndrome With Excess Blasts-1 +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [5].
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [5].
Myeloid Neoplasm +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].
Myeloid Sarcoma +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Neuroblastoma +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains BCR-ABL1 Fusion and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Plasma Cell Neoplasm +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains BCR-ABL1 Fusion and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [5].
Polycythemia Vera +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [5].
Primary Myelofibrosis +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Rhabdomyosarcoma +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains BCR-ABL1 Fusion and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Secondary Myelodysplastic Syndrome +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [5].
Small Lymphocytic Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains BCR-ABL1 Fusion and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [5].
Solid Neoplasm +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for solid neoplasm, of which 0 are open and 1 is closed. Of the trial that contains BCR-ABL1 Fusion and solid neoplasm as inclusion criteria, 1 is no phase specified (0 open) [5].
T-Cell Lymphoblastic Lymphoma +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for T-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and T-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].
T-Cell And NK-Cell Neoplasm +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Therapy-Related Chronic Myelomonocytic Leukemia +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].
Therapy-Related Myeloid Neoplasm +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for therapy-related myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and therapy-related myeloid neoplasm as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].
Waldenstrom Macroglobulinemia +
BCR-ABL1 Fusion is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 1 is open and 0 are closed. Of the trial that contains BCR-ABL1 Fusion and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 2 (1 open) [5].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
